<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28972192</article-id><article-id pub-id-type="pmc">5664308</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2017809046</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000004570</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>20</subject><subject>185</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Victor</surname><given-names>Ronald G.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Ronald G. Victor, MD has had contracted research with Eli Lilly, Capricor, and Catabasis. He has received travel compensation from Eli Lilly and has only received a personal consulting fee from Eli Lilly to help design/finalize the study protocol. Once the protocol was finalized, Eli Lilly then reimbursed Cedars-Sinai Medical Center for Dr. Victor?s time and effort serving as the global principal investigator for the Phase 3 tadalafil trial.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Ronald G. Victor, MD has had contracted research with Eli Lilly, Capricor, and Catabasis; he has received travel compensation from Eli Lilly and has only received a personal consulting fee from Eli Lilly to help design/finalize the study protocol. Once the protocol was finalized, Eli Lilly then reimbursed Cedars-Sinai Medical Center for Dr. Victor?s time and effort serving as the global principal investigator for the Phase 3 tadalafil trial.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Eli Lilly (global PI; site investigator) Capricor (site investigator) Catabasis (site investigator)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH grant: U34 AR062893 Role: PI Years: 6/2012-5/2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>I have received funding support for proof-of-concept studies related to this trial from the following foundations: (1) Parent Project Muscular Dystrophy, (2) Muscular Dystrophy Association, and (3) Coalition Duchenne.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Sweeney</surname><given-names>H. Lee</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1) Advisory Board for Lilly Phase 3 Randomized Placebo- Controlled Trial of Tadalafil for Duchenne Muscular Dystrophy- Commercial</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>World Muscle Society- Non-Profit; speaker honorarium</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>BMS</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH- See NIH reporter for details</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Parent Project Muscular Dystrophy</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Finkel</surname><given-names>Richard</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Cure SMA, medical advisory board, 2004-14 (2) SMA Foundation, medical advisory board, 2005-17 (3) SMA Europe, scientific advisory board, 2015-17 (4) SMA REACH, external advisor, 2015-17 (5) Nationwide Children's Hospital and AveXis, DSMB member (AVXS-101 phase 1 study), 2014-16 (6) Roche, DSMB member (MOONFISH study), 2015</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Cure SMA: funding for travel to speak at conferences, 2005-17 (2) SMA Foundation: funding for travel to attend workshops, 2007-17 (3) Muscular Dystrophy Assn: funding for travel to conferences, 2011-17 (4) Ionis Pharmaceuticals: speaker honoraria, funding for travel to speak at conferences and with regulatory authorities, 2013-17 (5) Biogen: speaker honoraria, funding for travel to speak at conferences and with regulatory authorities, 2013-17 (6) AveXis: speaker honoraria, funding for travel to speak at conferences and with regulatory authorities, 2015-17 (7) Roche: speaker honoraria, funding for travel to speak at conferences and with regulatory authorities, 2013-16 (7) Catabasis: funding for travel to speak with regulatory authorities, 2015-17 (8) Summit: funding for travel to speak with regulatory authorities, 2015-17 (9) World Muscle Society: honorarium, 2016</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial advisory board member without compensation: (1) Neuromuscular Disorders, 2010- (2) J. Neuromuscular Diseases, 2013- Spouse serves on the editorial board of Arthritis Research and Therapy without compensation, 1999-</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Patents held by spouse: 1. Finkel, T.H., Kubo, R.: Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associates. 2. Finkel, T.H., Kubo, R.: Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, NY. 3. Finkel, T.H., Kubo, R.: Anti- Human TCR Zeta mAb to Santa Cruz Biotechnology.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Swaiman's Pediatric Neurology, 6th edition; Elsevier, 2017.</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Ionis Pharmaceuticals: 2012-16 (2) Biogen: 2014-17 (3) Roche: 2015-17 (4) AveXis: 2015-17 (5) Novartis: 2015-17 (6) Mitobridge: 2015-16 (7) Capricor: 2017 (8) Lilly: 2015-16 (9) Summit: 2015-16</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>Approximately half of my time and effort is devoted to patient care, mainly children with neuromuscular disorders. Some of these patients are enrolled in clinical trials. The remainder of my time is spent in teaching, research and administrative activities.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Dr. Richard Finkel: (1) Ionis Pharmaceuticals, advisor, 2012-2013; investigator, 2013- 2016 (2) Biogen: advisor, 2014-17; investigator, 2015-17 (3) Eli Lilly Pharmaceuticals: investigator, 2013-16 (4) Cytokinetics: investigator, 2016-17 (5) ReveraGen: investigator, 2016-17 (7) BMS, investigator, 2016-17 (8) Summit, investigator, 2016-17 (8) Sarepta, investigator, 2015-17</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) 5U01NS061799, Co-I, 2010-17 (2) RO1AR056973, Co-I, 2010-17 (3) 1U54NS065712-01, Co-I, 2009-17</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Spinal Muscular Atrophy Foundation (2) Cure SMA (3) Muscular Dystrophy Association (5) Charcot-Marie-Tooth Association</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License fee payments, Technology or Inventions:</title><list-item><p>Spouse recieves licensing fee payments: 1. Finkel, T.H., Kubo, R.: Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associates. 2. Finkel, T.H., Kubo, R.: Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, NY. 3. Finkel, T.H., Kubo, R.: Anti-Human TCR Zeta mAb to Santa Cruz Biotechnology.</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>Craig M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) PTC Therapeutics, scientific advisory board concerning Duchenne muscular dystrophy, (2) Eli Lilly, scientific advisory committee concerning Duchenne muscular dystrophy, (3) Catabasis, scientific advisory Board, (4) Sarepta Therapeutics, scientific advisory board</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) PTC Therapeutics, speaker honorarium for Duchenne muscular dystrophy educational symposium, (2) Marathon, speaker honorarium for Duchenne muscular dystrophy educational symposium, and advisory board, (3) Catabasis, honoraria for educational symposium, (4) Sarepta Therapeutics, honoraria for regional advisory boards.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>National Institute of Disability and Rehabilitation Research Grant #H133B090001; Rehabilitation Research and Training Center in Neuromuscular Diseases: Enhancing Health and Wellness of Individuals with Neuromuscular Diseases. October 1, 2009 to September 30, 2015 - $4,000,000. Principal Investigator: Craig M. McDonald National Institutes of Arthritis, Musculoskeletal and Skin Diseases Research (NIAMS), Grant #1R01AR061875: Clinically Meaningful Outcomes for Duchenne Muscular Dystrophy Therapeutic Trials. September 1, 2011 to August 31, 2015 - $1,320,122 Principal Investigator: Craig M. McDonald, MD National Institutes of Arthritis, Musculoskeletal and Skin Diseases Research (NIAMS), Grant # 5R01AR062380: Biomarker discovery and validation in a Duchenne dystrophy natural history study. September 1, 2011 to August 31, 2015 - $1,318,122 Principal Investigator: Craig M. McDonald, MD Department of Defense Congressionally Directed Medical Research Program (CDMRP) Grant # MD130062; Grants.gov ID Number: GRANT11522309 Development of a lifespan-based novel composite person-reported outcome measure using data from the CINRG Duchenne natural history study. July 1, 2014 to June 30 2017, $1,001,162 Principal Investigator: Craig M. McDonald, MD Department of Defense Congressionally Directed Medical Research Program (CDMRP) Grant # MD160094; Grants.gov ID Number: GRANT12274832 Validation of novel community-based measures of physical activity in 2.5 year old children with Duchenne muscular dystrophy. July 1, 2017 to June 30 2020, $942,000 Principal Investigator: Craig M. McDonald, MD</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Muscular Dustrophy Association Clinical research Network in Duchenne Muscular Dystrophy, (2) Parent Project Muscular Dystrophy</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Byrne</surname><given-names>Barry</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Scientific Advisory Board - Pfizer, Inc.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editor - Human Gene Therapy Academic Editor - PLOS One</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Solid Biosciences - research support</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NIH, NHLBI - PI</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Cure FA Foundation - research support</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License fee payments, Technology or Inventions:</title><list-item><p>Inventor payments as regular compensation from the Univeristy of Florida.</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>University of Florida</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Eagle</surname><given-names>Michelle</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Catabasis PTC Capricor</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Commercial ATOM International Limited current employment</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>PTC GSK/PRosensa WAVE Acceleron Eli Lilly Sarepta Santhera Summit BMS Biomarin</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Goemans</surname><given-names>Nathalie</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Advisory Board PTC Therapeutics, Biogen, Summit, Bristol Meyers Squibb, Sarepta</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>PTC Therapeutics, Biogen, Sarepta, Biomarin</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editorial advisory board member Neuromuscular Disorders</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Biogen, Summit, Sarepta</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Duchenne Parent Project Rondou Duchenne Fonds</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Vandenborne</surname><given-names>Krista</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NIH Study Section Advisory board to an NIH grant</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Foundation as speaker</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) NIH R01AR05697 (2) NIH U54AR052646</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Parent Project Muscular Dystrophy</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dubrovsky</surname><given-names>Alberto L.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Genzyme PTC Amicus</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>European Medical Journal (Neurology) EB member 3 years Neurologia Argentina - EB 4 years</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Topaloglu</surname><given-names>Haluk</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>PTC Therapeutics for DMD clinical trial Glaxo-Simith-Kline for DMD clinical trial</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Miceli</surname><given-names>M. Carrie</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>1) enhancers of exon skipping pending 2)ca regulators of exon skipping pending not directly relevant to this study</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Furlong</surname><given-names>Pat</given-names></name><degrees>BSN</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Landry</surname><given-names>John</given-names></name><degrees>MMath</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) Eli Lilly Canada Inc., Research Scientist, 10 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>(1) Eli Lilly and Company</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Elashoff</surname><given-names>Robert</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Non profit, UCLA John Wayne Cancer Institute.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>David</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Eli Lilly and Company, full time employee, 1993 - present</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>Stock and stock options in Eli Lilly and Company, 1997- present</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><collab>For the Tadalafil DMD Study Group</collab></contrib><aff>From the Cedars-Sinai Medical Center (R.G.V.), Los Angeles, CA; University of Florida (H.L.S., B.B., K.V.), Gainesville; Nemours Children's Hospital (R.F.), Orlando, FL; University of California at Davis (C.M.M.), Sacramento; Newcastle University (M.E.), Newcastle Upon Tyne, UK; University Hospitals Leuven (N.G.), Belgium; Instituto de Neurociencias&#x02013;Fundacion Favaloro (A.L.D.), Buenos Aires, Argentina; Hacettepe University School of Medicine (H.T.), Ankara, Turkey; UCLA (M.C.M., R.E.), Los Angeles, CA; Parent Project Muscular Dystrophy (P.F.), Hackensack, NJ; Eli Lilly Canada, Eli Lilly and Company, Toronto, ON (J.L.); and Eli Lilly and Company (D.C.), Indianapolis, IN.</aff></contrib-group><contrib-group content-type="collaborators"><contrib contrib-type="collab"><collab>Tadalafil DMD Study Group</collab></contrib><contrib contrib-type="collab"><name><surname>Abdel-Hamid</surname><given-names>Hoda</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Apkon</surname><given-names>Susan</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barohn</surname><given-names>Richard</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Belousova</surname><given-names>Elena</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bertini</surname><given-names>Enrico</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Brandsema</surname><given-names>John</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bruno</surname><given-names>Claudio</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Burnette</surname><given-names>William</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Butterfield</surname><given-names>Russell</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Byrne</surname><given-names>Barry</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Campbell</surname><given-names>Craig</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Carlo</surname><given-names>Jose</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Chae</surname><given-names>Jong-Hee</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Chandratre</surname><given-names>Saleel</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Comi</surname><given-names>Giacomo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Connolly</surname><given-names>Anne</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>De Groot</surname><given-names>Imelda</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Deconinck</surname><given-names>Nicolas</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dooley</surname><given-names>Joseph</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dubrovsky</surname><given-names>Alberto</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Durigneux</surname><given-names>Julien</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Finanger</surname><given-names>Erika</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Finkel</surname><given-names>Richard</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Frank</surname><given-names>L. Matthew</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Goemans</surname><given-names>Nathalie</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Harper</surname><given-names>Amy</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Hattori</surname><given-names>Ayako</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Herguner</surname><given-names>Ozlem</given-names></name><role>Prof. Dr</role></contrib><contrib contrib-type="collab"><name><surname>Iannaccone</surname><given-names>Susan</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Janas</surname><given-names>Joanne</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Jong</surname><given-names>Yuh-Jyh</given-names></name><degrees>MD, D.M.Sci</degrees></contrib><contrib contrib-type="collab"><name><surname>Kirschner</surname><given-names>JanBerd</given-names></name><role>Prof. Dr. med</role></contrib><contrib contrib-type="collab"><name><surname>Komaki</surname><given-names>Hirofumi</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kuntz</surname><given-names>Nancy</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Lee</surname><given-names>Wang-Tso</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Leung</surname><given-names>Edward</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mah</surname><given-names>Jean</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mathews</surname><given-names>Katherine</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>McDonald</surname><given-names>Craig</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mercuri</surname><given-names>Eugenio</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>McMillan</surname><given-names>Hugh</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mueller-Felber</surname><given-names>Wolfgang</given-names></name><role>Prof. Dr. med</role></contrib><contrib contrib-type="collab"><name><surname>Lopez de Munain</surname><given-names>Adolfo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Nakamura</surname><given-names>Akinori</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Niks</surname><given-names>Erik</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Ogata</surname><given-names>Katsuhisa</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pascual</surname><given-names>Samuel</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pegoraro</surname><given-names>Elena</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pereon</surname><given-names>Yann</given-names></name><degrees>MD, PhD</degrees><role>HDR</role></contrib><contrib contrib-type="collab"><name><surname>Renfroe</surname><given-names>Ben</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sanka</surname><given-names>Ratna Bhavaraju</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Schallner</surname><given-names>Jens</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Schara</surname><given-names>Ulrike</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Selby</surname><given-names>Kathryn</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sendra</surname><given-names>Isabel Illa</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Servais</surname><given-names>Laurent</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Smith</surname><given-names>Edward</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Sparks</surname><given-names>Susan</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Topaloglu</surname><given-names>Haluk</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Victor</surname><given-names>Ron</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vilchez</surname><given-names>Juan Jose</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wicklund</surname><given-names>Matthew</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wilichoswki</surname><given-names>Ekkehard</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Wong</surname><given-names>Brenda</given-names></name><degrees>MD</degrees></contrib></contrib-group><author-notes><corresp>Correspondence to: Dr. Victor: <email>Ronald.victor@cshs.org</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by The Burns and Allen Chair in Cardiology Research at the Cedars-Sinai Heart Institute.</p></fn><fn fn-type="other"><p>Coinvestigators are listed at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link>.</p></fn></author-notes><pub-date pub-type="ppub"><day>24</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>89</volume><issue>17</issue><fpage>1811</fpage><lpage>1820</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2017809046.pdf"/><abstract><sec><title>Objective:</title><p>To conduct a randomized trial to test the primary hypothesis that once-daily tadalafil, administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD).</p></sec><sec><title>Methods:</title><p>Three hundred thirty-one participants with DMD 7 to 14 years of age taking glucocorticoids were randomized to tadalafil 0.3 mg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;d<sup>&#x02212;1</sup>, tadalafil 0.6 mg&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;d<sup>&#x02212;1</sup>, or placebo. The primary efficacy measure was 6-minute walk distance (6MWD) after 48 weeks. Secondary efficacy measures included North Star Ambulatory Assessment and timed function tests. Performance of Upper Limb (PUL) was a prespecified exploratory outcome.</p></sec><sec><title>Results:</title><p>Tadalafil had no effect on the primary outcome: 48-week declines in 6MWD were 51.0 &#x000b1; 9.3 m with placebo, 64.7 &#x000b1; 9.8 m with low-dose tadalafil (<italic>p</italic> = 0.307 vs placebo), and 59.1 &#x000b1; 9.4 m with high-dose tadalafil (<italic>p</italic> = 0.538 vs placebo). Tadalafil also had no effect on secondary outcomes. In boys &#x0003e;10 years of age, total PUL score and shoulder subscore declined less with low-dose tadalafil than placebo. Adverse events were consistent with the known safety profile of tadalafil and the DMD disease state.</p></sec><sec><title>Conclusions:</title><p>Tadalafil did not lessen the decline in ambulatory ability in boys with DMD. Further studies should be considered to confirm the hypothesis-generating upper limb data and to determine whether ambulatory decline can be slowed by initiation of tadalafil before 7 years of age.</p></sec><sec><title>Clinicaltrials.gov identifier:</title><p>NCT01865084.</p></sec><sec><title>Classification of evidence:</title><p>This study provides Class I evidence that tadalafil does not slow ambulatory decline in 7- to 14-year-old boys with Duchenne muscular dystrophy.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>triangle</meta-value></custom-meta><custom-meta><meta-name>cme</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><italic>Dystrophin</italic> mutations cause the most common muscular dystrophy, Duchenne muscular dystrophy (DMD), a devastating x-linked muscle-wasting disease.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Boys are diagnosed as toddlers, and most lose ambulation by 12 to 15 years of age. Average life expectancy is &#x02248;30 years due to respiratory failure and cardiomyopathy.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Corticosteroids can prolong ambulation by 2 to 3 years, reduce the risk of scoliosis, and temper pulmonary and possibly cardiac decline, but they cause well-known side effects.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Thus, a more effective therapy is an urgent need.</p><p>Dystrophin is both a structural sarcolemma-stabilizing protein and a scaffolding protein that targets partner proteins to the sarcolemma.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> Among these is a muscle-specific variant of neuronal nitric oxide (NO) synthase (nNOS<sub>&#x003bc;</sub>), the main enzymatic source of NO in skeletal muscle.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Sarcolemmal nNOS<sub>&#x003bc;</sub> increases its enzymatic activity and thus NO&#x02013;cyclic guanosine monophosphate (cGMP) signaling during exercise<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and is implicated in muscle blood flow regulation and mitochondrial biogenesis, microtubule organization, and sarcolemmal targeting of other dystrophin-associated proteins.<sup><xref rid="R7" ref-type="bibr">7</xref><xref ref-type="bibr" rid="R8">&#x02013;</xref><xref rid="R10" ref-type="bibr">10</xref></sup> The NO generated modulates adrenergic vasoconstriction in exercising skeletal muscle, thereby optimizing perfusion (a protective mechanism called functional sympatholysis).<sup><xref rid="R11" ref-type="bibr">11</xref><xref ref-type="bibr" rid="R12">&#x02013;</xref><xref rid="R13" ref-type="bibr">13</xref></sup> In DMD, dystrophin deficiency disrupts sarcolemma targeting of nNOS<sub>&#x003bc;</sub>,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> contributing to dystrophic muscle pathology<sup><xref rid="R7" ref-type="bibr">7</xref><xref ref-type="bibr" rid="R8">&#x02013;</xref><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> and causing defective blood flow regulation.<sup><xref rid="R15" ref-type="bibr">15</xref><xref ref-type="bibr" rid="R16">&#x02013;</xref><xref rid="R17" ref-type="bibr">17</xref></sup> Consequently, repeated bouts of functional muscle ischemia could accelerate use-dependent injury of skeletal muscle fibers already weakened by loss of dystrophin.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><p>A compelling body of preclinical research in mouse, zebrafish, and dog models of DMD implicates the NO-cGMP pathway as a putative new drug target for DMD.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R19" ref-type="bibr">19</xref><xref ref-type="bibr" rid="R20">&#x02013;</xref><xref rid="R30" ref-type="bibr">30</xref></sup> Short-term dosing of tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor that boosts defective NO-cGMP signaling in skeletal muscle microvessels, prevents exercise-induced muscle ischemia, injury, and fatigue in mdx mice.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Short-term dosing of tadalafil also ameliorates forearm muscle ischemia during handgrip exercise in boys with DMD<sup><xref rid="R15" ref-type="bibr">15</xref></sup> and men with Becker muscular dystrophy,<sup><xref rid="R31" ref-type="bibr">31</xref></sup> a milder form of dystrophinopathy. Whether these effects translate to a meaningful clinical benefit is unknown.</p><p>Accordingly, we conducted a phase 3 clinical trial to test the primary hypothesis that once-daily tadalafil, administered orally for 48 weeks, lessens the decline in ambulatory ability in boys with DMD. In addition, we explored the effect on upper limb function due to its slower decline.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Standard protocol approvals, registrations, and patient consents.</title><p>The study protocol and consent forms were approved by the institutional review/ethics boards at each participating medical center and conducted in accordance with the Declaration of Helsinki and other international ethics guidelines. Written informed consent was obtained from parents or guardians, and written assent was obtained from participants. This trial is registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01865084).</p></sec><sec id="s1-2"><title>Participants.</title><p>The diagnostic criteria for DMD were onset of clinical signs or symptoms before 6 years of age, markedly high serum creatine kinase level, and deletion or duplication <italic>dystrophin</italic> mutation or nearly absent dystrophin protein on muscle biopsy.<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p><p>Inclusion criteria were male with proven DMD, age of 7 to 14 years, 6-minute walk distance (6MWD) between 200 and 400 m, 2 baseline 6MWDs differing by &#x0003c;20%, left ventricular ejection fraction &#x02265;50%, and systemic corticosteroid therapy for &#x02265;6 months with a stable regimen &#x02265;3 months. Exclusion criteria were heart failure; rhythm other than sinus or abnormal conduction on ECG; continuous mechanical ventilation; medication other than corticosteroids affecting muscle strength; other conditions affecting muscle performance; history of renal insufficiency, retinal disorder, hypotension, or uncontrolled hypertension; or cytochrome P450 3A4 inhibitor treatment.</p></sec><sec id="s1-3"><title>Study design.</title><p>We conducted a phase 3 randomized, placebo-controlled, parallel 3-arm trial of tadalafil in patients with DMD in 63 sites in 15 countries.</p></sec><sec id="s1-4"><title>Randomization and blinding.</title><p>Randomization was 1:1:1 (computer-generated random sequence) to placebo, tadalafil 0.3 mg/kg (low dose), or tadalafil 0.6 mg/kg (high dose). Randomization was stratified by site and baseline 6MWD &#x0003c;300 or &#x02265;300 m. Siblings were assigned to the same group. Total daily dose was determined by baseline weight. All participants received the same number of identical-appearing tablets. Patients, parents/guardians, investigators, evaluators, and other study staff were blinded to group assignment.</p></sec><sec id="s1-5"><title>Procedures.</title><sec id="s1-5-1"><title>Evaluation of the primary outcome and other efficacy measures.</title><p>The primary efficacy measure was the 6MWD assessed with a 6-minute walk test modified for boys with DMD (standardized verbal encouragement and a safety chaser).<sup><xref rid="R33" ref-type="bibr">33</xref></sup> The 6MWD was assessed twice at baseline and once every 12 weeks thereafter.</p><p>Secondary efficacy measures included the North Star Ambulatory Assessment (NSAA), a 17-item evaluation of standing ability and other timed function tests.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> The total raw NSAA score was transformed to a linear 0-to-100 scale. Data are expressed as time to perform each test, the physical therapist's score, and velocity.</p><p>Exploratory efficacy measures included the Performance of Upper Limb (PUL), pulmonary function, and resting heart rate. Total PUL scale (0&#x02013;72 points) is a functional assessment for upper limb activities of daily living that includes a total of 22 individual tests of motor performance with subscores at the level of the shoulder (high level, 0&#x02013;16 points), elbow (midlevel, 0&#x02013;32 points), and hand/fingers (distal level, 0&#x02013;24 points). A prespecified subgroup analysis was done for boys with DMD &#x0003e;10 years of age, the age at which the total PUL scale begins to decline, with a proximal-to-distal gradient.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Substudies aimed to explore leg muscle fat fraction by MRI at 4 centers and functional sympatholysis at 1 center.</p><p>Evaluators were trained physical therapists/physiotherapists. Assessments were performed in the same order (NSAA, 4-stair climb/descend, PUL, and 6MWD) generally at the same time of day.</p><p>The Pediatric Outcomes Data Collection Instrument was the main quality-of-life assessment.<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p></sec><sec id="s1-5-2"><title>Drug exposures.</title><p>Population pharmacokinetic modeling was used to estimate steady-state tadalafil exposures. Blood samples were collected at various time intervals after dosing. Data are expressed as the mean area under the concentration-time curve (AUC).</p></sec><sec id="s1-5-3"><title>Safety.</title><p>Safety measures included adverse events, laboratory data, vital signs, physical growth, ECGs, and echocardiograms.</p></sec></sec><sec id="s1-6"><title>Statistics.</title><p>Assuming an SD of 60 m, 102 patients per group provided 90% estimated power to detect a between-group difference of 30 m in change in 6MWD, which is clinically meaningful.<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p><p>Efficacy analyses on the full dataset were by intention to treat. A mixed-effects model with repeated measurements (MMRM) was used to test the primary null hypothesis of no difference between tadalafil and placebo in mean change in 6MWD at 48 weeks. The model included a continuous fixed effect for baseline 6MWD and fixed categorical effects of group assignment, visit, group-by-visit interaction, and country. Secondary and exploratory efficacy measures also were analyzed by MMRM. Fisher exact test was applied to categorical safety measures to flag potential treatment differences.</p><p>A multiplicity adjustment controlled for global type I error. Tests of the primary hypothesis and those conducted under the multiplicity adjustment are considered scientifically confirmatory, while all others are considered hypothesis generating.</p><p>Prespecified subgroup analyses were conducted on the primary outcome by baseline 6MWD &#x0003c;300 or &#x02265;300 m and PUL scores/subscores by baseline age &#x02264;10 or &#x0003e;10 years. Subgroup analyses used MMRM with addition of subgroup, subgroup-by-treatment interaction, and subgroup-by-treatment-by-visit interaction. For each subgroup analysis, a significant interaction was defined at the 0.10 level.</p></sec><sec id="s1-7"><title>Primary research question.</title><p>Does daily tadalafil treatment lessen the decline in ambulatory ability in boys with DMD?</p></sec><sec id="s1-8"><title>Classification of evidence.</title><p>This study provides Class I evidence that tadalafil does not slow ambulatory decline in 7- to 14-year old boys with DMD who are taking corticosteroids.</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p>The first patient enrolled in September 2013, and the last patient visit for the double-blind trial was in December 2015. An open-label extension study was stopped in January 2016 because tadalafil had no effect on the primary and secondary efficacy endpoints of the trial. Here, we report the major outcomes of the double-blind trial.</p><sec id="s2-1"><title>Patient characteristics.</title><p>In total, 331 patients were randomized and 316 patients completed the trial (<xref ref-type="fig" rid="F1">figure 1</xref>). One patient randomized to high-dose tadalafil was excluded from the safety analysis because he discontinued before the first dose, but his data were included in the efficacy analysis.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Patient disposition</title></caption><graphic xlink:href="NEUROLOGY2017809046FF1"/></fig><p>Baseline characteristics were similar across treatment groups, with some exceptions (<xref ref-type="table" rid="T1">table 1</xref>). On average, patients in the placebo group were younger and had a higher baseline 6MWD compared to those in the tadalafil groups, and a smaller proportion of patients in the placebo group had a baseline 6MWD &#x0003c;300 m. The proportion of patients unable to rise from floor independently and unable to perform the 4-stair climbing and descending tasks was higher in the low-dose tadalafil group compared with the placebo and high-dose tadalafil groups. A higher proportion of boys in the placebo group were taking deflazacort (<xref ref-type="table" rid="T1">table 1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics and baseline characteristics</p></caption><graphic xlink:href="NEUROLOGY2017809046TT1"/></table-wrap></sec><sec id="s2-2"><title>Primary efficacy measure.</title><p>Tadalafil had no effect on the primary outcome. After 48 weeks, 6MWD declined by &#x02212;51.0 &#x000b1; 9.3 m with placebo vs &#x02212;64.7 &#x000b1; 9.8 m with low-dose tadalafil (<italic>p</italic> = 0.307 vs placebo) and &#x02212;59.1 &#x000b1; 9.4 m with high-dose tadalafil (<italic>p</italic> = 0.538 vs placebo) (<xref ref-type="fig" rid="F2">figure 2</xref>). Baseline values of 6MWD and percent of predicted 6MWD were slightly less in the tadalafil groups; however, both measures declined in parallel regardless of group assignment (<xref ref-type="fig" rid="F2">figure 2</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mean change in efficacy measures</title><p>(A) Mean change from baseline to week 48 in 6MWD. (B) Mean change from baseline to week 48 in NSAA (linearized score on scale of 0&#x02013;100). (C) Mean 6MWD (meters), baseline to week 48. (D) Mean percent of predicted 6MWD, baseline to week 48. *Primary efficacy endpoint. Analyses for each efficacy parameter included all patients with nonmissing baseline and at least 1 nonmissing postbaseline value (for 6MWD: n = 113 in placebo, 101 in tadalafil 0.3 mg/kg, and 111 for tadalafil 0.6 mg/kg; for NSAA: n = 116 in placebo, 102 in tadalafil 0.3 mg/kg, and 112 for tadalafil 0.6 mg/kg). LS = least squares; NSAA = North Star Ambulatory Assessment; 6MWD = 6-minute walk distance.</p></caption><graphic xlink:href="NEUROLOGY2017809046FF2"/></fig><p>After 48 weeks, 37.9% of participants in the placebo group experienced persistent 10% worsening in 6MWD compared with 37.3% in the low-dose tadalafil group (<italic>p</italic> = 1.000) and 44.2% in the high-dose tadalafil group (<italic>p</italic> = 0.350); 7 (6.0%) participants in the placebo group lost ambulation compared to 16 (15.7%) in the low-dose tadalafil group (<italic>p</italic> = 0.027) and 9 (8.0%) in the high-dose tadalafil group (<italic>p</italic> = 0.613).</p><p>As expected, 6MWD declined more steeply in patients with baseline 6MWD &#x0003c;300 m. However, tadalafil had no effect on either subgroup (figure e-1 at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link>).</p></sec><sec id="s2-3"><title>Secondary efficacy measures.</title><p>Tadalafil had no effect on secondary outcomes. NSAA data are shown in <xref ref-type="fig" rid="F2">figure 2B</xref> and figure e-2, and timed function test data are given in tables e-1 and e-2 and figure e-3. The only statistically positive finding was a smaller decline in velocity of the rise from floor with low-dose tadalafil, but the difference compared with placebo was trivial (figure e-3).</p><p>Tadalafil had no effect on the decline in parent-rated quality of life (figure e-4). Data are not reported for adolescent self-rated data because the numbers of adolescent participants were too small (7&#x02013;11 per group).</p></sec><sec id="s2-4"><title>Exploratory efficacy measures.</title><sec id="s2-4-1"><title>PUL.</title><p>As expected, PUL declined only in the prespecified subgroup of boys &#x0003e;10 years of age (n = 75). Their total PUL score and shoulder subscore declined less with low-dose tadalafil (n = 33) than placebo (n = 20) (<xref ref-type="fig" rid="F3">figure 3</xref>). After 48 weeks, total PUL score declined by 4% with placebo vs 1% with low-dose tadalafil (<italic>p</italic> = 0.02) and shoulder subscore by 14% with placebo vs 4% with low-dose tadalafil (<italic>p</italic> = 0.04). Total PUL score and shoulder subscore also tended to decline less (<italic>p</italic> &#x0003e; 0.1) with high-dose tadalafil (n = 22) than placebo. The age-by-treatment interaction <italic>p</italic> value was 0.056 and 0.060 for the total PUL score and shoulder subscore, respectively. Elbow and hand/finger scores were unchanged with placebo and tadalafil even in older boys (figure e-5).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Mean change in total and shoulder level PUL score</title><p>(A) Total PUL score in the total population (n = 114 in placebo, 99 in tadalafil 0.3 mg/kg, and 107 in tadalafil 0.6 mg/kg). (B) Total PUL score in patients &#x02264;10 years of age (n = 95 in placebo, 68 in tadalafil 0.3 mg/kg, and 85 in tadalafil 0.6 mg/kg). (C) Total PUL score in patients &#x0003e;10 years of age (n = 19 in placebo, 31 in tadalafil 0.3 mg/kg, and 22 in tadalafil 0.6 mg/kg). (D) Shoulder-level PUL subscore in the total population (n = 116 in placebo, 101 in tadalafil 0.3 mg/kg, and 111 in tadalafil 0.6 mg/kg). (E) Shoulder-level PUL subscore in patients &#x02264;10 years of age (n = 96 in placebo, 69 in tadalafil 0.3 mg/kg, and 89 in tadalafil 0.6 mg/kg). (F) Shoulder-level PUL subscore in patients &#x0003e;10 years of age (n = 20 in placebo, 32 in tadalafil 0.3 mg/kg, and 22 in tadalafil 0.6 mg/kg). Changes in total PUL score are from a total score range of 0 to 72; changes in shoulder-level PUL are from a total score range of 0 to 16. Higher score represents better function. Analyses for each efficacy parameter included all patients with nonmissing baseline and at least 1 nonmissing postbaseline value. *<italic>p</italic> &#x0003c; 0.05. LS = least squares; PUL = Performance of Upper Limb.</p></caption><graphic xlink:href="NEUROLOGY2017809046FF3"/></fig></sec><sec id="s2-4-2"><title>Pulmonary function.</title><p>Pulmonary function tests showed little, if any, decline, as expected for this age group, with no treatment effect (table e-3).</p></sec><sec id="s2-4-3"><title>Resting heart rate.</title><p>Resting heart rate by ECG tended to be slightly lower with tadalafil treatment, but this tendency was not statistically significant. After 48 weeks, heart rate tended to decline by 1.6 bpm from baseline with placebo compared with 3.8 bpm with low-dose tadalafil (<italic>p</italic> = 0.182 vs placebo) and 2.4 bpm with high-dose tadalafil (<italic>p</italic> = 0.635 vs placebo).</p></sec><sec id="s2-4-4"><title>Substudies.</title><p>Data are not reported because too few participants completed either the leg fat MRI substudy (n = 9 per group) or the sympatholysis substudy (n = 2 or 3 per group).</p></sec></sec><sec id="s2-5"><title>Compliance and drug concentration measurements.</title><p>Mean compliance in all groups exceeded 97% at every visit. Tadalafil steady-state mean AUCs were 6550 ng &#x000b7;h/mL and 9380 ng &#x000b7; h/mL during dosing with 0.3 and 0.6 mg/kg, respectively. Participant-specific data showed no association between tadalafil AUC values and changes in 6MWD (figure e-6).</p></sec><sec id="s2-6"><title>Safety.</title><p>Serious adverse events (SAEs), treatment-emergent adverse events, or adverse events leading to discontinuation were similar across groups (<xref ref-type="table" rid="T2">table 2</xref>). Adverse events related to study drug were reported in 41.4%, 50.0%, and 59.8% of patients in the placebo, low-dose, and high-dose tadalafil groups, respectively; the difference between high-dose tadalafil and placebo was significant (<italic>p</italic> = 0.006). The treatment-emergent adverse events of &#x0201c;erection increased&#x0201d; with high-dose tadalafil (15.2%, <italic>p</italic> &#x0003c; 0.001) and &#x0201c;spontaneous penile erection&#x0201d; with low-dose tadalafil (12.7%, <italic>p</italic> = 0.012) and high-dose tadalafil (11.6%, <italic>p</italic> = 0.023) were reported at a higher frequency than with placebo. Individual SAEs (table e-4) were consistent with the type of events expected for patients with DMD receiving corticosteroid therapy; the most frequently reported SAEs were falls, fractures, and infections. No deaths occurred.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Adverse events</p></caption><graphic xlink:href="NEUROLOGY2017809046TT2"/></table-wrap><p>Changes in left ventricular ejection fraction were small with no group differences (table e-5). There were no differences between the tadalafil and placebo groups in safety monitoring data by laboratory parameters, vital signs, height, body weight, or ECG.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>In the largest DMD clinical trial to date and the first to explore upper limb performance, 48 weeks of tadalafil did not lessen the decline in 6MWD or other measures of ambulatory ability in boys with DMD 7 to 14 years of age receiving standard glucocorticoid therapy. Yet, in a prespecified subgroup analysis of boys &#x0003e;10 years of age, tadalafil was associated with a lesser decline in upper limb function.</p><p>That tadalafil caused no discernible stabilization of ambulatory ability stands in marked contrast to the solid preclinical foundation of the trial, involving 3 different models. In the mdx mouse, multiple genetic and pharmacologic strategies that boost NO-cGMP signaling, including short- or long-term dosing of PDE5 inhibitors, markedly ameliorate many features of the dystrophic phenotype.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R26" ref-type="bibr">26</xref><xref ref-type="bibr" rid="R27">&#x02013;</xref><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> In mdx mice, even short-term dosing of either tadalafil or sildenafil abrogates muscle ischemia, injury, and fatigue after downhill (eccentric) treadmill exercise<sup><xref rid="R23" ref-type="bibr">23</xref></sup> and doubles horizontal walking distance, the mouse equivalent of 6MWD.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> Long-term sildenafil rescues dystrophic skeletal and cardiac muscle and prolongs survival in dystrophin-deficient zebrafish,<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and long-term tadalafil improves skeletal muscle histopathology and delays the onset of cardiomyopathy in the virulent large-animal golden retriever model.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p><p>A short-term dosing study conducted in boys with DMD 8 to 13 years of age taking corticosteroids informed the tadalafil doses for this clinical trial.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Tadalafil improved blood flow regulation in exercising forearm muscle in a dose-dependent manner without affecting blood flow in resting forearm muscle. The oral tadalafil was dosed short term at 0.5 or 1.0 mg/kg (approximating maximum adult doses for erectile dysfunction or pulmonary hypertension, respectively). For transition to once-daily administration in the trial, doses are 30% lower because tadalafil has a long elimination half-life and thus accumulates in plasma.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p><p>Several other strengths of the trial design include the unprecedented DMD sample size and outstanding cohort retention and medication compliance with pharmacokinetic proof that the study achieved desired levels of 24-hour drug exposure. In our pediatric DMD participants, the 2 daily tadalafil doses produced steady-state drug concentrations that were comparable to those achieved when healthy adults are given the maximal allowable daily doses<sup><xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> but unrelated to individual differences in the primary study outcome of 6MWD. Thus, the negative primary and secondary outcomes were not due to insufficient statistical power or drug exposure. We do not believe the negative outcomes are explained by the somewhat lower mean baseline values of 6MWD in the tadalafil groups because baseline 6MWD was a covariate in the primary analysis and no tadalafil effect was seen when the analysis was stratified by baseline 6MWD &#x0003e;30 or 300 m.</p><p>In the placebo group, the decline in total PUL score, mainly from a decline in shoulder function, confirms natural history data in DMD showing progressive decline in PUL after, but not before, age 10 with a proximal-to-distal gradient.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> In older boys, the slower decline in shoulder function and thus total PUL score with low-dose tadalafil should be interpreted cautiously and considered hypothesis generating. The lack of significant treatment effect with high-dose tadalafil may be due to this smaller sample of the subgroup. Thus, without further study, the treatment effect seen with low-dose tadalafil is of uncertain clinical significance.</p><p>However, the PUL data raise 2 potential explanations for the negative primary outcome of the trial. Because DMD progresses faster in lower than in upper extremities, the boys in this trial may not have engaged in enough daily ambulation and fatiguing leg exercise for the drug to prevent use-dependent leg muscle injury. In DMD, the therapeutic target of tadalafil, defective NO-cGMP signaling in skeletal muscle microvessels, regulates muscle blood flow only when the muscles are active.<sup><xref rid="R15" ref-type="bibr">15</xref><xref ref-type="bibr" rid="R16">&#x02013;</xref><xref rid="R17" ref-type="bibr">17</xref></sup> Because PDE5 levels were found in 1 study to be lower than normal in leg muscle biopsy tissue of 4 adult men with Becker muscular dystrophy,<sup><xref rid="R38" ref-type="bibr">38</xref></sup> another possibility is that the cellular target of the drug (PDE5) was lacking in DMD leg muscle microvessels.</p><p>While PDE5 inhibitors improve cardiac function in preclinical models of DMD,<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> a cardiac MRI study reported that systolic function possibly declined more rapidly in 8 adult patients with DMD cardiomyopathy treated with sildenafil than in 7 patients treated with placebo.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> While those results might be related to sample size or more advanced cardiomyopathy at baseline in the sildenafil group,<sup><xref rid="R39" ref-type="bibr">39</xref></sup> we augmented cardiac safety monitoring of our pediatric patients with serial echocardiograms, which showed no adverse effect of tadalafil on cardiac function. Overall, safety monitoring revealed the expected increase in penile erections with tadalafil without priapism.</p><p>Our study has some important limitations in methodology. Despite the expertise and training of the physical therapists who conducted the outcome evaluations using state-of-the-art clinical trial methodology,<sup><xref rid="R33" ref-type="bibr">33</xref></sup> the 6-minute walk test and other current tests used to assess ambulatory (and upper limb) ability in DMD all are invariably influenced by the boys' volition. MRI measurement of muscle fat fraction is a more sensitive nonvolitional index of DMD disease progression<sup><xref rid="R40" ref-type="bibr">40</xref></sup>; however, our exploratory leg muscle MRI substudy sample was too small to be informative. We could not document the extent to which tadalafil improved muscle blood flow regulation during the trial because the sympatholysis substudy sample was too small. However, our previous study strongly suggests that these doses of tadalafil should have improved muscle blood flow regulation at least during arm exercise.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p>On the basis of the present findings, it remains unknown whether defective blood flow regulation during exercise in dystrophic human skeletal muscle is merely a reliable biomarker of defective nNOS<sub>&#x000b5;</sub> signaling or remains a viable therapeutic target. Further studies should be considered both to confirm the hypothesis-generating upper limb data and to determine whether ambulatory decline in DMD can be slowed by initiation of PDE5 inhibition before 7 years of age.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_89_17_1811__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_WNL.0000000000004570_e-Tables.doc"/>
<media xlink:role="associated-file" mimetype="application"
mime-subtype="vnd.ms-powerpoint"
xlink:href="supp_WNL.0000000000004570_e-Figures.ppt"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Coinvestigators</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_89_17_1811_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_WNL.0000000000004570_Coinvestigators_-_Victor.doc"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank all the participants and their families, all the site investigators (coinvestigator list is available at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link>), and staff for their dedication and commitment to the trial. They also thank the physiotherapist training team (Lindsay Alfano, PT; Kristy Rose Cocayne, PhD; Michelle Eagle, PhD; Julaine Florence, DPT; Meredith James, Linda Lowes, PhD; Anna Mayhew, PhD; Elena Mazzone, PT; and Leslie Nelson, MPT), Ann Martin, MS, GSC from DuchenneConnect, and Stephen Lynn, PhD, from TREAT-NMD for recruitment assistance, David Small, PhD, and Lisa Ferguson-Sells (Global PK/PD, Eli Lilly and Company) for analysis of tadalafil exposure data, Deborah D'Souza, PhD, MBA (InVentiv Clinical, LLC), for formatting assistance under the direction of the authors, Yvonne Kobayashi, PhD (research scientist, Eli Lilly and Company), for helpful scientific discussions, and Theresa Bauer (Clinical Trial Management, Eli Lilly and Company), whose tireless commitment was essential to the successful implementation and completion of this trial.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">R.G. Victor contributed to the conception and design of the study, chaired the Steering Committee, served as the global principal investigator and a site investigator, participated in the interpretation of the data, wrote the first draft of the manuscript, wrote and approved the final version of the manuscript, had access to all the data, and takes overall responsibility for the data and accuracy of the data analysis. H.L. Sweeney participated in the conception and design of the study, was a member of the Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. R. Finkel participated in the conception and design of the study, was a site investigator and member of the trial Steering Committee for which he chaired the Publications Subcommittee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. C.M. McDonald participated in the conception and design of the study, was a site investigator and a member of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during development, and approved the final manuscript. B. Byrne was a site investigator and was a member of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. M. Eagle led the physiotherapist training team and oversaw implementation of the functional tests in the trial, was a member of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. N. Goemans was a site investigator and a member of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. K. Vandenborne contributed to the design of the MRI substudy, was a member of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. A.L. Dubrovsky and H. Topaloglu were site investigators, participated in the interpretation of the data, critically reviewed the manuscript during development, and approved the final manuscript. M.C. Miceli and P. Furlong were members of the trial Steering Committee, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final manuscript. J. Landry participated in the study design, supervised the statistical analyses, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. R. Elashoff contributed to the conception and design of the study, participated in the interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript. D. Cox participated in the design of the study and the analysis and interpretation of the data, critically reviewed the manuscript during its development, and approved the final version of the manuscript.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study was funded by Eli Lilly and Company.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">R. Victor has had contracted research with Eli Lilly, Capricor, and Catabasis; he has received travel compensation from Eli Lilly and has received a consulting fee from Eli Lilly, which reimburses Cedars-Sinai Medical Center for Dr. Victor's time and effort serving as the global principal investigator for the phase 3 tadalafil trial. H. Sweeney provided consulting as a member of the trial Steering Committee but received no payments for this activity. R. Finkel has served on advisory boards and/or received travel support and compensation from Ionis, Biogen, Roche, AveXis, Catabasis, Summit, and PTC. C. McDonald reports clinical trial support from Acceleron Pharma, Bristol Myers Squibb, Cardero Therapeutics, Eli Lilly and Company, Halo, Novartis, NS Pharma, and ReveraGen BioPharma; consulting and research support from BioMarin; consulting and clinical trial support from Italfarmaco; consulting, clinical trial, and research support from Pfizer, PTC Therapeutics, and Santhera Therapeutics; consulting, clinical trials, advisory board, or research support from Marathon Pharmaceuticals and Sarepta Therapeutics; consulting for Catabasis Pharmaceuticals; speaking and research support from Parent Project Muscular Dystrophy; speaking support from Collaborative Clinical Trajectory Project, CureDuchenne, Duchenne Regulatory Science Consortium, and TREAT-NMD; and research support from Muscular Dystrophy Association. B. Byrne reports no disclosures relevant to the manuscript. M. Eagle has disclosures for paid consulting with PTC, Summit, Biomarin, Bristol Myers Squibb, Italfarmaco, Santhera, Sarepta, Catabasis, and Capricor. N. Goemans has served on advisory boards for Summit, Biogen, PTC, and BioMarin; she has received travel support and compensations as a speaker at symposia from PTC, BioMarin, and Biogen. K. Vandenborne reports grants from Eli Lilly, Sarepta Therapeutics, Catabasis Pharmaceuticals, Pfizer, Italfarmaco SpA, and Summit Therapeutics. A. Dubrovsky disclosures that he is a member of the Global Advisory Board for Pompe Disease from Genzyme; he received research grants and speaker honoraria from Genzyme (Sanofi); and he received travel expenses and speaker honoraria from PTC and BioMarin. H. Topaloglu reports no disclosures relevant to the manuscript. M. Miceli serves on the Solid Therapeutic Scientific Advisory Board for Gene Therapy and has patents issued or pending (US2012/053157 national phase/PCT patent filed: Identification of small molecules that enhance therapeutic exon skipping, Nelson/Miceli/Moran; UC- 2014-258-1, provisional patent filed, Calmodulin inhibitors enhance DMD exon 51 skipping in a patient cell line, Miceli/Nelson/Kendell). P. Furlong reports no disclosures relevant to the manuscript. J. Landry is an employee of Eli Lilly and possesses shares of Eli Lilly stock. R. Elashoff reports no disclosures relevant to the manuscript. D. Cox is an employee and stockholder of Eli Lilly and Company. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004570">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AUC</term><def><p>area under the concentration-time curve</p></def></def-item><def-item><term id="G2">cGMP</term><def><p>cyclic guanosine monophosphate</p></def></def-item><def-item><term id="G3">DMD</term><def><p>Duchenne muscular dystrophy</p></def></def-item><def-item><term id="G4">MMRM</term><def><p>mixed-effects model with repeated measurement</p></def></def-item><def-item><term id="G5">NO</term><def><p>nitric oxide</p></def></def-item><def-item><term id="G6">nNOS&#x003bc;</term><def><p>muscle-specific splice variant of neuronal nitric oxide synthase</p></def></def-item><def-item><term id="G7">NSAA</term><def><p>North Star Ambulatory Assessment</p></def></def-item><def-item><term id="G8">PDE5</term><def><p>phosphodiesterase type 5</p></def></def-item><def-item><term id="G9">PUL</term><def><p>Performance of Upper Limb</p></def></def-item><def-item><term id="G10">SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term id="G11">6MWD</term><def><p>6-minute walk distance</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Kinnett</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rodger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vroom</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Furlong</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Aartsma-Rus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bushby</surname><given-names>K</given-names></name></person-group>
<article-title>Imperatives for DUCHENNE MD: a simplified guide to comprehensive care for Duchenne muscular dystrophy</article-title>. <source>PLoS Curr</source> Epub 2015 Aug 7.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mah</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Korngut</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dykeman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pringsheim</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jette</surname><given-names>N</given-names></name></person-group>
<article-title>A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy</article-title>. <source>Neuromuscul Disord</source>
<year>2014</year>;<volume>24</volume>:<fpage>482</fpage>&#x02013;<lpage>491</lpage>.<pub-id pub-id-type="pmid">24780148</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ervasti</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Ohlendieck</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kahl</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Gaver</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>KP</given-names></name></person-group>
<article-title>Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle</article-title>. <source>Nature</source>
<year>1990</year>;<volume>345</volume>:<fpage>315</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">2188135</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>RH</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Kunkel</surname><given-names>LM</given-names></name></person-group>
<article-title>Dystrophin: the protein product of the Duchenne muscular dystrophy locus</article-title>. <source>Cell</source>
<year>1987</year>;<volume>51</volume>:<fpage>919</fpage>&#x02013;<lpage>928</lpage>.<pub-id pub-id-type="pmid">3319190</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenman</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Chao</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Aldape</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bredt</surname><given-names>DS</given-names></name></person-group>
<article-title>Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy</article-title>. <source>Cell</source>
<year>1995</year>;<volume>82</volume>:<fpage>743</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">7545544</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy</article-title>. <source>J Clin Invest</source>
<year>2009</year>;<volume>119</volume>:<fpage>624</fpage>&#x02013;<lpage>635</lpage>.<pub-id pub-id-type="pmid">19229108</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Palma</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Morisi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pambianco</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation</article-title>. <source>Skelet Muscle</source>
<year>2014</year>;<volume>4</volume>:<fpage>22</fpage>.<pub-id pub-id-type="pmid">25530838</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Froehner</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>KN</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Percival</surname><given-names>JM</given-names></name></person-group>
<article-title>Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice</article-title>. <source>Hum Mol Genet</source>
<year>2015</year>;<volume>24</volume>:<fpage>492</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">25214536</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Balke</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Madorma</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Nitric oxide regulates skeletal muscle fatigue, fiber type, microtubule organization, and mitochondrial ATP synthesis efficiency through cGMP-dependent mechanisms</article-title>. <source>Antioxid Redox Signal</source>
<year>2017</year>;<volume>26</volume>:<fpage>966</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">27393340</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebolledo</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Whitehead</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Froehner</surname><given-names>SC</given-names></name></person-group>
<article-title>Sarcolemmal targeting of nNOS<sub>&#x000b5;</sub> improves contractile function of mdx muscle</article-title>. <source>Hum Mol Genet</source>
<year>2016</year>;<volume>25</volume>:<fpage>158</fpage>&#x02013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">26604149</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Victor</surname><given-names>RG</given-names></name></person-group>
<article-title>Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle</article-title>. <source>J Clin Invest</source>
<year>1996</year>;<volume>98</volume>:<fpage>584</fpage>&#x02013;<lpage>596</lpage>.<pub-id pub-id-type="pmid">8755671</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Rosenberry</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Barresi</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy</article-title>. <source>J Physiol (London)</source>
<year>2015</year>;<volume>593</volume>:<fpage>5183</fpage>&#x02013;<lpage>5200</lpage>.<pub-id pub-id-type="pmid">26437761</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Victor</surname><given-names>RG</given-names></name></person-group>
<article-title>Inhibition of alpha 2-adrenergic vasoconstriction during contraction of glycolytic, not oxidative, rat hind limb muscle</article-title>. <source>Am J Physiol</source>
<year>1994</year>;<volume>266</volume>:<fpage>H920</fpage>&#x02013;<lpage>H929</lpage>.<pub-id pub-id-type="pmid">7909201</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Whitehead</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Froehner</surname><given-names>SC</given-names></name></person-group>
<article-title>Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca<sup>2+</sup>, reactive oxygen species, and nitric oxide in the development of muscular dystrophy</article-title>. <source>Physiol Rev</source>
<year>2016</year>;<volume>96</volume>:<fpage>253</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">26676145</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group>
<article-title>PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy</article-title>. <source>Neurology</source>
<year>2014</year>;<volume>82</volume>:<fpage>2085</fpage>&#x02013;<lpage>2091</lpage>.<pub-id pub-id-type="pmid">24808022</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chavoshan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2000</year>;<volume>97</volume>:<fpage>13818</fpage>&#x02013;<lpage>13823</lpage>.<pub-id pub-id-type="pmid">11087833</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Sander</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Stull</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Victor</surname><given-names>RG</given-names></name></person-group>
<article-title>Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1998</year>;<volume>95</volume>:<fpage>15090</fpage>&#x02013;<lpage>15095</lpage>.<pub-id pub-id-type="pmid">9844020</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rando</surname><given-names>TA</given-names></name></person-group>
<article-title>Role of nitric oxide in the pathogenesis of muscular dystrophies: a &#x0201c;two hit&#x0201d; hypothesis of the cause of muscle necrosis</article-title>. <source>Microsc Res Tech</source>
<year>2001</year>;<volume>55</volume>:<fpage>223</fpage>&#x02013;<lpage>235</lpage>.<pub-id pub-id-type="pmid">11748861</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamo</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Percival</surname><given-names>JM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2010</year>;<volume>107</volume>:<fpage>19079</fpage>&#x02013;<lpage>19083</lpage>.<pub-id pub-id-type="pmid">20956307</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asai</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sahani</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kaneki</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ouchi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Martyn</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Yasuhara</surname><given-names>SE</given-names></name></person-group>
<article-title>Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy</article-title>. <source>PLoS One</source>
<year>2007</year>;<volume>2</volume>:<fpage>e806</fpage>.<pub-id pub-id-type="pmid">17726536</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammers</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Sleeper</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Forbes</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Shima</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Walter</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Sweeney</surname><given-names>HL</given-names></name></person-group>
<article-title>Tadalafil treatment delays the onset of cardiomyopathy in dystrophin-deficient hearts</article-title>. <source>J Am Heart Assoc</source>
<year>2016</year>;<volume>5</volume>:<fpage>e003911</fpage>.<pub-id pub-id-type="pmid">27506543</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawahara</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Karpf</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Guyon</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Kunkel</surname><given-names>LM</given-names></name></person-group>
<article-title>Drug screening in a zebrafish model of Duchenne muscular dystrophy</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2011</year>;<volume>108</volume>:<fpage>5331</fpage>&#x02013;<lpage>5336</lpage>.<pub-id pub-id-type="pmid">21402949</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>RW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sarcolemma-localized nNOS is required to maintain activity after mild exercise</article-title>. <source>Nature</source>
<year>2008</year>;<volume>456</volume>:<fpage>511</fpage>&#x02013;<lpage>515</lpage>.<pub-id pub-id-type="pmid">18953332</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Rader</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>KP</given-names></name></person-group>
<article-title>Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies</article-title>. <source>Neuromuscul Disord</source>
<year>2012</year>;<volume>22</volume>:<fpage>34</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">22154712</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percival</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Whitehead</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Adamo</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Beavo</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Froehner</surname><given-names>SC</given-names></name></person-group>
<article-title>Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy</article-title>. <source>J Pathol</source>
<year>2012</year>;<volume>228</volume>:<fpage>77</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">22653783</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Shaul</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Yuhanna</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Froehner</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>ME</given-names></name></person-group>
<article-title>Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase</article-title>. <source>Circ Res</source>
<year>2003</year>;<volume>92</volume>:<fpage>554</fpage>&#x02013;<lpage>560</lpage>.<pub-id pub-id-type="pmid">12600881</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uaesoontrachoon</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Tatem</surname><given-names>KS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy</article-title>. <source>Hum Mol Genet</source>
<year>2014</year>;<volume>23</volume>:<fpage>3239</fpage>&#x02013;<lpage>3249</lpage>.<pub-id pub-id-type="pmid">24463621</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wehling-Henricks</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Roos</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tidball</surname><given-names>JG</given-names></name></person-group>
<article-title>Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium</article-title>. <source>Hum Mol Genet</source>
<year>2005</year>;<volume>14</volume>:<fpage>1921</fpage>&#x02013;<lpage>1933</lpage>.<pub-id pub-id-type="pmid">15917272</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wehling</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Tidball</surname><given-names>JG</given-names></name></person-group>
<article-title>A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice</article-title>. <source>J Cell Biol</source>
<year>2001</year>;<volume>155</volume>:<fpage>123</fpage>&#x02013;<lpage>131</lpage>.<pub-id pub-id-type="pmid">11581289</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy</article-title>. <source>Hum Mol Genet</source>
<year>2013</year>;<volume>22</volume>:<fpage>3720</fpage>&#x02013;<lpage>3729</lpage>.<pub-id pub-id-type="pmid">23681067</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Barresi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Byrne</surname><given-names>BJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy</article-title>. <source>Sci Transl Med</source>
<year>2012</year>;<volume>4</volume>:<fpage>162ra155</fpage>.</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pane</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mazzone</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Fanelli</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy</article-title>. <source>Neuromuscul Disord</source>
<year>2014</year>;<volume>24</volume>:<fpage>201</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">24440357</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henricson</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Abresch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>JJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year</article-title>. <source>PLoS Curr</source>
<year>2013</year>;<volume>5</volume>:<fpage>ecurrents.md.9e17658b007eb79fcd6f723089f79e06</fpage>.<pub-id pub-id-type="pmid">23867975</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayhew</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Cano</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy</article-title>. <source>Dev Med Child Neurol</source>
<year>2013</year>;<volume>55</volume>:<fpage>1046</fpage>&#x02013;<lpage>1052</lpage>.<pub-id pub-id-type="pmid">23909763</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Nardi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Monopoli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ongini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Victor</surname><given-names>RG</given-names></name></person-group>
<article-title>Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy</article-title>. <source>PLoS One</source>
<year>2012</year>;<volume>7</volume>:<fpage>e49350</fpage>.<pub-id pub-id-type="pmid">23139842</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forgue</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Bedding</surname><given-names>AW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Tadalafil pharmacokinetics in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source>
<year>2006</year>;<volume>61</volume>:<fpage>280</fpage>&#x02013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">16487221</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrishko</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Dingemanse</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects</article-title>. <source>J Clin Pharmacol</source>
<year>2008</year>;<volume>48</volume>:<fpage>610</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">18305126</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witting</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kruuse</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nyhuus</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy</article-title>. <source>Ann Neurol</source>
<year>2014</year>;<volume>76</volume>:<fpage>550</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">25042931</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Herzka</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>WR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy</article-title>. <source>Ann Neurol</source>
<year>2014</year>;<volume>76</volume>:<fpage>541</fpage>&#x02013;<lpage>549</lpage>.<pub-id pub-id-type="pmid">25042693</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willcocks</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Arpan</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Forbes</surname><given-names>SC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression</article-title>. <source>Neuromuscul Disord</source>
<year>2014</year>;<volume>24</volume>:<fpage>393</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">24491484</pub-id></mixed-citation></ref></ref-list></back></article>